1. An Introduction to Danish Life Science
- and Medicon Valley
Bangalore INDIA BIO 2011

2. AGENDA
BIOTECH IN
DENMARK
MEDICON
VALLEY
3 August, 2011

3. Denmark & Medicon valley
3 August, 2011

4. BIOTECH IN
DENMARK
The Danish Life Sciences Cluster - facts
- 7 science parks - 25 CROs
- 8 universities - ≥ 160 core biotech
- 75 hospitals (4 major university companies
hospitals) - ≥ 180 core medtech
- 10,000 life science graduates companies
annually - 48,000 employees in the life
- 2,000 LS PhDs students science industry
graduating annually

5. BIOTECH IN
DENMARK
DENMARK COMPARES WELL
and it is not just something we say...
• Denmark is among the five countries in the world (and 2nd
in Europe) with the most likely potential for development
of biotechnology
(Scientific American 2010)

• The 3rd best overall biotech sector in the world
(fDi Magazine, 2008)
• Stable funding situation in the middle of a financial storm
(Ernst and Young 2010)
• The 3rd largest commercial drug development pipeline in
Europe (in actual numbers)
(Ernst and Young 2010)

6. BIOTECH IN
DENMARK
Denmark – European TOP 3 position (pipeline)
Preclinical: Phase I: Phase II: Phase III:
Research
69 59 58 40
(Total commercial drug development pipeline in Denmark Source: Invest
in Denmark, 2010; Copenhagen Capacity 2010)
6 Source: Ernst & Young, Beyond borders 2010

7. BIOTECH IN
DENMARK
THE POOL OF BIOTECH´S KEEPS GROWING
New Biotech Start-ups in Denmark
20
18
16
14
Antal start-ups
12
10
8
6
4
2
0
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
1925-1950
1951-1975
1976-1985
1986-1990
1991-1995
until 1925
7 Source: Danish Biotech Ass., December 2009

8. BIOTECH IN
DENMARK
TOTAL NUMBER OF BIOTECH COMPANIES IN DENMARK
180
160
140
120
Antal virksomheder
100
80
60
40
20
0
Indtil…
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
8 Source: Danish Biotech Ass., December 2009

9. BIOTECH IN
DENMARK
Denmark is among the largest exporters per capita of
pharmaceutical products
Development in Danish drug exports 1997-2010:
60
50
40
Billion DKK
30
20
10
0
1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010

10. INVEST IN
DENMARK
THE DANISH LIFE SCIENCE CLUSTER HOLDS AREAS OF
GLOBAL BUSINESS EXCELLENCE & STRONGHOLDS
BIOTECH MEDTECH ICT
CANCER DIAGNOSTICS
ASSITIVE
METABOLIC
TECHNOLOGY
CNS DISPOSABLES
INFLAMATORY &
INFECTION DISEASES
ROBOTICS
HEALTHCARE IT

11. BIOTECH IN
DENMARK
Danish competences – Biotech cluster
Areas of Business Excellences Biotech strongholds
(Technological platforms)
- Cancer/oncology - Biomedical Informatics
- CNS/Neuroscience - Clinical Trials
- Personalized Medicine
- Metabolic diseases
- Proteomics
- Inflammatory and Infectious diseases - Nanomedicine
- Drug Delivery
- Vaccines

12. BIOTECH IN
DENMARK
Life Science centres in Denmark
Science Parks
Innovation Incubators
University Hospitals

13. 7 Science Parks
The Science Parks holds:
• Incubator solutions
• Access to VC’s- from pre-seed to seed
• A facilitating and knowledge-sharing
environment
• Access to state-of-the-art lab facilities
• Cost-competitive m2 prices
• Usually located close to the universities

14. 6 Innovation Incubators
The purpose of the innovation incubator scheme is to create and
develop more knowledge-intensive start-ups with unique skills
Innovation incubators:
• seeks out and screen risky commercialization ideas
invest in commercialization ideas
• ensure access to appropriate facilities for the knowledge-based
entrepreneurship
• advise entrepreneurs on how to maturation the commercializing idea
• help entrepreneurs to build contacts with private investors to attracted
capital

15. BIOTECH IN
DENMARK
CLUSTERS IN DENMARK Northern Jutland/Aalborg
• Biomedical technology
Central Jutland/Aarhus
• Biotech/Biomedical
technology/Food
innovation
Funen/Odense
• Biomedical technology
Copenhagen area
• Medicon Valley

16. MEDICON
VALLEY
MEDICON VALLEY

17. MEDICON
VALLEY
MEDICON VALLEY – one of Europe´s strongest life
science clusters
1997 2011

18. MEDICON
VALLEY
MEDICON VALLEY – BASIC FACTS & FIGURES
Population: 3.5 mill. 44.000 life-science
7 large R&D based employees in the private
pharma companies with sector
local roots 9 science parks
App.150 biotechs with 11 universities (5 supply
own R&D life science educations)
App. 200 medtech 155.000 students (app
companies 1/3 in Life Sciences)
More than 50 CROs and More than a dozen VCs
CMOs with experienced life
33 hospitals (of which 11 science teams
are university hospitals)
18

19. MEDICON
VALLEY
MEDICON VALLEY STRONGHOLDS
• Global leadership in diabetes and
obesity
• World-class R&D in CNS
• Very strong R&D tradition in other
important therapeutic areas, e.g.
inflammation, infectious diseases,
immunology and oncology
• Emerging position in the field of
personalized medicine

20. MEDICON
VALLEY
MEDICON VALLEY – where tradition meets the future
Tradition: Novo Nordisk, LEO
Pharma, Lundbeck, Nycomed,
Ferring, ALK Albello
Stars of the future: Bavarian
Nordic, Neurosearch, Zealand
Pharma, Genmab, Santaris
Pharma, Symphogen, Lifecycle
Pharma, Action Pharma, Exiqon

21. BIOTECH IN
DENMARK
Danish headline deal makers (selected examples)
• Topotarget and Spectrum Pharmaceuticals (2010)
• Genmab : GSK (2006) and TenX (2010)
• LEO : Buy-back of US psoriasis portfolio from Warner-Chilcott (2009)
• LEO : Acquisition of Peplin (AU) for USD 287.5 mill. (2009)
• Santaris: Enzon (2006), GSK (2007), Wyeth (2009) and Shire (2009)
• Neurosearch: Abbot (1999), GSK (2003) and Eli Lilly (2009), Janssen
(2009)
• Symphogen: Meiji Seika (2006), Genentech (2008), Origen (2009)
• Upfront Chromatography and Cangene (2009)
• Egalet and RedHill Biopharma (2009)
• Nuevolution: Merck(2008)
• Lundbeck: Ovation acquisition (2008)
• Zealand: Sanofi-Aventis (2003) and Helsinn (2008)
• Zymenex : Divestment of Metazym to Shire (2008)
• Exiqon: OncoTech acquisition (2007)
• Lifecycle : Mylan (2006), Sandoz (2006) and Sciele (2007)
www.mediconvalley.com

22. BIOTECH IN
DENMARK
Business Solutions
Choose DK for your next R&D Center
 Choose DK for your SalesMarketing office
 Choose DK for Biopharmaceutical Production
 Choose DK for your North European HQ
 The Best Environment for conducting Clinical Trials

23. BIOTECH IN
DENMARK
Denmark’s best business framework
• Flexicurity – easy hire and lay off practices
• Best labour relations in the world
• Human resources - World’s most motivated and best trained
labour force
• Flexible and cooperative government – no red tape
• 2nd most stable political environment in the world
• 25% corporate tax
• 3rd best infrastructure in the world
• Economic top performer

24. BIOTECH IN
DENMARK
Assistance from INVEST IN DENMARK
• Identification of specific business opportunities
Potential partners
• Comprehensive fact base and decision-making support
Taxation, employment laws, regulatory issues
• Local contacts
IP consultants, lawyers, authorities & public/private
co-operation partners
• Tools – unique benchmark, cost/benefit & logistic tools

25. For more information , Pls contact below :
PRAMILA DAS , MSc, MBA
Investment Manager, LifeSciences
INVEST IN DENMARK– INDIA OFFICE
M +91 99456 96801
DIR: 91 80 4157 0057
EMAIL PRADAS@UM.DK
TRADE COMMISSION OF DENMARK
142, 4th Main Road, Defence Colony
Indiranagar, BANGALORE - 560 038
Tel: +91 (80) 4157 0057
WWW.INVESTINDK.COM